Evaluation of matched PB and BM samples from B-ALL patients post induction therapy indicated higher PD-1 expression on BM T cells, with PD-1 and LAG3 levels further upregulated on CD4+ and CD8+ T cells following ex vivo expansion (69). The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.